GlassScriptPhysician profile
Lillian Ingram
NPI 1942564711
$8,257.52
in general payments reported to CMS, 2019-2025
22 companies · $3,892 in 2025
The $3,892 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $369 · 2023: $669 · 2024: $3,143 · 2025: $3,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,393 · Consulting Fee: $1,395 · Travel and Lodging: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,392.79 |
| Consulting Fee | $1,395.00 |
| Travel and Lodging | $917.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,355.82 | 2024-2025 | Spravato, Invega Sustenna, Invega |
| E.R. Squibb & Sons, L.L.C. | $1,690.82 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $864.04 | 2023-2025 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $694.48 | 2021-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $484.88 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $449.02 | 2021-2025 | |
| Indivior INC. | $291.31 | 2024-2025 | Sublocade, Perseris |
| Alkermes, INC. | $286.71 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.95 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $212.04 | 2023-2025 | Ingrezza |
| Mayne Pharma Commercial LLC | $123.81 | 2022 | |
| Axsome Therapeutics, INC. | $115.52 | 2025 | Auvelity |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Acadia Pharmaceuticals INC | $113.05 | 2022 | |
| Almatica Pharma LLC | $55.30 | 2024-2025 | Loreev Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $47.61 | 2024 | |
| Corium, LLC | $26.77 | 2024 | Azstarys |
| Lundbeck LLC | $23.25 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $16.10 | 2021 | |
| Vanda Pharmaceuticals INC. | $15.16 | 2025 | Fanapt |
| Tris Pharma INC | $13.73 | 2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $13.15 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.